Cellectar Biosciences, Inc.

CLRB

US15117F8077

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 01:30:00 06/06/2024 am IST			5-day change	1st Jan Change
3.11 ^USD	+7.43%		+5.42%	+12.27%

29/05	Cellectar Biosciences, Inc. and City of Hope Cancer Center Enter Collaboration to Evaluate Iopofosine I 131 in Mycosis fungoides	CI
14/05	Transcript : Cellectar Biosciences, Inc., Q1 2024 Earnings Call, May 14, 2024

Cellectar Biosciences, Inc. Announces Resignation of John E. Friend Ii as Vice President and Chief Medical Officer, Effective November 27, 2018

November 17, 2018 at 02:32 am IST

Cellectar Biosciences, Inc. announced that John E. Friend II, M.D. resigned as Vice President and Chief Medical Officer, effective November 27, 2018.

Latest news about Cellectar Biosciences, Inc.

Cellectar Biosciences, Inc. and City of Hope Cancer Center Enter Collaboration to Evaluate Iopofosine I 131 in Mycosis fungoides	29/05	CI
Transcript : Cellectar Biosciences, Inc., Q1 2024 Earnings Call, May 14, 2024	14/05
Cellectar Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	14/05	CI
Roth MKM Raises Cellectar Biosciences' Price Target to $28 From $20, Retains Buy Rating	28/03	MT
Oppenheimer Adjusts Cellectar Biosciences Price Target to $12 From $11, Maintains Outperform Rating	28/03	MT
Transcript : Cellectar Biosciences, Inc., 2023 Earnings Call, Mar 27, 2024	27/03
Cellectar Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	27/03	CI
Cellectar Biosciences, Inc. Reports High Rate of Complete Remission in Investigator Initiated Phase I Study of iopofosine in Combination with External Beam Radiotherapy in Recurrent Head and Neck Cancer	04/03	CI
Cellectar Biosciences, Inc. Announces Enrollment of the First Patient in Pediatric High-Grade Gliomas Phase 1B Clinical Study	30/01	CI
Sector Update: Health Care Stocks Advance Late Afternoon	23/01	MT
Cellectar Biosciences Shares Rise as Drug Shows Promise on Complete Central Nervous System Clearance on Cancer Type	23/01	MT
Cellectar Biosciences, Inc. Reports Complete Central Nervous System Clearance in Relapsed/Refractory Waldenstrom?s Macroglobulinemia Patient	22/01	CI
Transcript : Cellectar Biosciences, Inc. - Special Call	19/01
Cellectar Biosciences Broadens Pipeline with Targeted Alpha Therapy for Solid Tumors and Releases Promising Preclinical Data	16/01	CI
Cellectar Biosciences Partners with MiBA to Advance the Treatment of Waldenstrom's Macroglobulinemia in the Community Setting	11/01	CI
Oppenheimer Boosts Price Target on Cellectar Biosciences to $11 From $8, Maintains Outperform Rating	09/01	MT
Global markets live: Merck, Honda, Novartis, Boeing, Nvidia...	08/01
Investors lower their expectations	08/01
Transcript : Cellectar Biosciences, Inc. - Special Call	08/01
Cellectar's blood cancer therapy succeeds in late-stage study	08/01	RE
Cellectar's blood cancer therapy succeeds in trial	08/01	RE
Cellectar Biosciences Announces Positive Topline Data Achieving Primary Endpoint in Pivotal Clinical Study of Iopofosine I 131 in Waldenstrom's Macroglobulinemia	08/01	CI
Cellectar Biosciences Expands Iopofosine I 131 Collaboration with Wisconsin Alumni Research Foundation	19/12	CI
Cellectar Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	13/11	CI
Transcript : Cellectar Biosciences, Inc., Q3 2023 Earnings Call, Nov 02, 2023	02/11

Chart Cellectar Biosciences, Inc.

Duration

Period

More charts

Cellectar Biosciences, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The Company, through phospholipid ether drug conjugate (PDC) delivery platform, is focused on developing PDCs that are designed to specifically target cancer cells. Its PDC platform possesses the potential for the discovery and development of cancer-targeting treatments, and it plans to develop PDCs both independently and through research and development collaborations. Its product pipeline includes iopofosine, a small-molecule PDC designed to provide targeted delivery of iodine-131 (radioisotope), preclinical PDC chemotherapeutic programs and multiple partnered PDC assets. Its Iopofosine is evaluated in the completed CLOVER-WaM Phase 2 pivotal study in patients with relapsed/refractory (r/r) Waldenstromâs macroglobulinemia (WM).

Sector

Pharmaceuticals

Calendar

14/06/2024 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

3.11 USD

Average target price

15 USD

Spread / Average Target

+382.32%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
CELLECTAR BIOSCIENCES, INC.	+12.27%	111M
ELI LILLY AND COMPANY	+42.69%	749B
NOVO NORDISK A/S	+38.96%	605B
JOHNSON & JOHNSON	-6.87%	351B
MERCK & CO., INC.	+18.74%	328B
ABBVIE INC.	+6.76%	292B
ASTRAZENECA PLC	+18.23%	248B
ROCHE HOLDING AG	-3.11%	214B
NOVARTIS AG	+10.97%	216B
PFIZER, INC.	+2.64%	167B

Other Pharmaceuticals